Shreyans Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 9:47 am

Competitors of Shreyans Industries Ltd

All Competitor Stocks of Shreyans Industries Ltd

Quarterly Result

Last Updated: August 20, 2025, 3:40 am

Below is a detailed analysis of the quarterly data for Shreyans Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 179.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 25.00 Cr..
• For Expenses, as of Jun 2025, the value is 138.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 152.00 Cr. (Mar 2025) to 138.00 Cr., marking a decrease of 14.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 11.00 Cr..
• For OPM %, as of Jun 2025, the value is 10.00%. The value appears to be declining and may need further review. It has decreased from 15.00% (Mar 2025) to 10.00%, marking a decrease of 5.00%.
• For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 8.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 2.00 Cr..
• For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Mar 2025) to 23.00%, marking a decrease of 2.00%.
• For Net Profit, as of Jun 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 12.49. The value appears to be declining and may need further review. It has decreased from 13.35 (Mar 2025) to 12.49, marking a decrease of 0.86.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:27 am

Growth

Last Updated: September 5, 2025, 1:31 pm

Balance Sheet

Last Updated: June 16, 2025, 11:21 am

Below is a detailed analysis of the balance sheet data for Shreyans Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 413.00 Cr.. The value appears strong and on an upward trend. It has increased from 369.00 Cr. (Mar 2024) to 413.00 Cr., marking an increase of 44.00 Cr..
• For Borrowings, as of Mar 2025, the value is 45.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 34.00 Cr. (Mar 2024) to 45.00 Cr., marking an increase of 11.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 144.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 143.00 Cr. (Mar 2024) to 144.00 Cr., marking an increase of 1.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 615.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 560.00 Cr. (Mar 2024) to 615.00 Cr., marking an increase of 55.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 236.00 Cr.. The value appears strong and on an upward trend. It has increased from 219.00 Cr. (Mar 2024) to 236.00 Cr., marking an increase of 17.00 Cr..
• For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 224.00 Cr. (Mar 2024) to 240.00 Cr., marking an increase of 16.00 Cr..
• For Other Assets, as of Mar 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 104.00 Cr. (Mar 2024) to 129.00 Cr., marking an increase of 25.00 Cr..
• For Total Assets, as of Mar 2025, the value is 615.00 Cr.. The value appears strong and on an upward trend. It has increased from 560.00 Cr. (Mar 2024) to 615.00 Cr., marking an increase of 55.00 Cr..

Notably, the Reserves (413.00 Cr.) exceed the Borrowings (45.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Shreyans Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 36.60. This value is within the healthy range. It has decreased from 63.24 (Mar 24) to 36.60, marking a decrease of 26.64.
• For Diluted EPS (Rs.), as of Mar 25, the value is 36.60. This value is within the healthy range. It has decreased from 63.24 (Mar 24) to 36.60, marking a decrease of 26.64.
• For Cash EPS (Rs.), as of Mar 25, the value is 47.79. This value is within the healthy range. It has decreased from 73.06 (Mar 24) to 47.79, marking a decrease of 25.27.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.46. It has increased from 277.01 (Mar 24) to 308.46, marking an increase of 31.45.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 308.46. It has increased from 277.01 (Mar 24) to 308.46, marking an increase of 31.45.
• For Dividend / Share (Rs.), as of Mar 25, the value is 5.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 5.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 446.13. It has decreased from 505.74 (Mar 24) to 446.13, marking a decrease of 59.61.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 63.17. This value is within the healthy range. It has decreased from 95.89 (Mar 24) to 63.17, marking a decrease of 32.72.
• For PBIT / Share (Rs.), as of Mar 25, the value is 51.98. This value is within the healthy range. It has decreased from 86.07 (Mar 24) to 51.98, marking a decrease of 34.09.
• For PBT / Share (Rs.), as of Mar 25, the value is 49.01. This value is within the healthy range. It has decreased from 83.00 (Mar 24) to 49.01, marking a decrease of 33.99.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 36.60. This value is within the healthy range. It has decreased from 63.23 (Mar 24) to 36.60, marking a decrease of 26.63.
• For PBDIT Margin (%), as of Mar 25, the value is 14.15. This value is within the healthy range. It has decreased from 18.96 (Mar 24) to 14.15, marking a decrease of 4.81.
• For PBIT Margin (%), as of Mar 25, the value is 11.65. This value is within the healthy range. It has decreased from 17.01 (Mar 24) to 11.65, marking a decrease of 5.36.
• For PBT Margin (%), as of Mar 25, the value is 10.98. This value is within the healthy range. It has decreased from 16.41 (Mar 24) to 10.98, marking a decrease of 5.43.
• For Net Profit Margin (%), as of Mar 25, the value is 8.20. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 8.20, marking a decrease of 4.30.
• For Return on Networth / Equity (%), as of Mar 25, the value is 11.86. This value is below the healthy minimum of 15. It has decreased from 22.82 (Mar 24) to 11.86, marking a decrease of 10.96.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.81. This value is within the healthy range. It has decreased from 27.57 (Mar 24) to 14.81, marking a decrease of 12.76.
• For Return On Assets (%), as of Mar 25, the value is 8.22. This value is within the healthy range. It has decreased from 15.60 (Mar 24) to 8.22, marking a decrease of 7.38.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.10. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.10, marking an increase of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.34 (Mar 24) to 1.05, marking a decrease of 0.29.
• For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.46 (Mar 24) to 2.61, marking an increase of 0.15.
• For Quick Ratio (X), as of Mar 25, the value is 2.24. This value exceeds the healthy maximum of 2. It has increased from 2.06 (Mar 24) to 2.24, marking an increase of 0.18.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.37. This value exceeds the healthy maximum of 8. It has decreased from 13.68 (Mar 24) to 12.37, marking a decrease of 1.31.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.66. This value is below the healthy minimum of 20. It has increased from 7.90 (Mar 24) to 13.66, marking an increase of 5.76.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.46. This value is below the healthy minimum of 20. It has increased from 6.84 (Mar 24) to 10.46, marking an increase of 3.62.
• For Earning Retention Ratio (%), as of Mar 25, the value is 86.34. This value exceeds the healthy maximum of 70. It has decreased from 92.10 (Mar 24) to 86.34, marking a decrease of 5.76.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.54. This value exceeds the healthy maximum of 70. It has decreased from 93.16 (Mar 24) to 89.54, marking a decrease of 3.62.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 21.22. This value is within the healthy range. It has decreased from 31.17 (Mar 24) to 21.22, marking a decrease of 9.95.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 13.29. This value is within the healthy range. It has decreased from 21.55 (Mar 24) to 13.29, marking a decrease of 8.26.
• For Enterprise Value (Cr.), as of Mar 25, the value is 268.11. It has decreased from 320.42 (Mar 24) to 268.11, marking a decrease of 52.31.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.45 (Mar 24) to 0.43, marking a decrease of 0.02.
• For EV / EBITDA (X), as of Mar 25, the value is 3.07. This value is below the healthy minimum of 5. It has increased from 2.42 (Mar 24) to 3.07, marking an increase of 0.65.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.42 (Mar 24) to 0.37, marking a decrease of 0.05.
• For Retention Ratios (%), as of Mar 25, the value is 86.33. This value exceeds the healthy maximum of 70. It has decreased from 92.09 (Mar 24) to 86.33, marking a decrease of 5.76.
• For Price / BV (X), as of Mar 25, the value is 0.54. This value is below the healthy minimum of 1. It has decreased from 0.76 (Mar 24) to 0.54, marking a decrease of 0.22.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.42 (Mar 24) to 0.37, marking a decrease of 0.05.
• For EarningsYield, as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has decreased from 0.29 (Mar 24) to 0.21, marking a decrease of 0.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness